Arch Fam Med
Institution: STANFORD Univ Med Center  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 2 No. 1, January 1993 TABLE OF CONTENTS
  •  Online Features
  Clinical Review
 This Article
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

RU 486

The Progesterone Antagonist

Barry D. Weiss, MD

Arch Fam Med. 1993;2(1):63-69.

Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.

1. Ulmann A. The antiprogestins: a recent advance in fertility regulation. J Steroid Biochem Mol Biol. 1987;27:1009-1112.
2. Baulieu EE. The steroid hormone antagonist RU-486: mechanism at the cellular level and clinical applications. Endocrinol Metab Clin North Am. 1991;20:873-891. PUBMED
3. Baulieu EE, Ulmann A, Philbert D. Contragestation by antiprogestin RU-486: a review. Arch Gynecol Obstet. 1987;241:73-85. PUBMED
4. Smith S, Kelly R. The effect of the antiprogestins RU-486 and ZK 98734 on the synthesis and metabolism of prostaglandins F2{alpha} and E2 in separated cells from early human decidua. J Clin Endocrinol Metab. 1987;65:527-534. FREE FULL TEXT
5. Kelly RW, Bukman A. Antiprogestagenic inhibition of uterine prostaglandin inactivation: a permissive mechanism for uterine stimulation. J Steroid Biochem Mol Biol. 1990;37:97-101. PUBMED
6. Garfield RE, Gasc JM, Baulieu EE. Effects of the antiprogesterone RU-486 on preterm birth in the rat. Am J Obstet Gynecol. 1987;157:1281-1285. PUBMED
7. Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F. The new steroid analog RU-486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab. 1984;59:25-28. FREE FULL TEXT
8. Baulieu EE. RU-486: an antiprogestin with contragestive activity in women. In: Baulieu EE, Segal SJ, eds. The Antiprogestin Steroid RU-486 and Human Fertility Control. New York, NY: Plenum Press; 1985:1-25.
9. Ulmann A. Uses of RU-486 for contragestation: an update. Contraception. 1987;36(suppl):27-30. PUBMED
10. Lamberts SWJ, Koper FW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU-486). J Clin Endocrinol Metab. 1991;73:187-191. FREE FULL TEXT
11. Heikinheimo O, Ylikorkala O, Lähteenmäki P. Antiprogesterone RU-486: a drug for non-surgical abortion. Ann Med. 1990;22:75-84. PUBMED
12. Baulieu EE. Contragestation by the progesterone antagonist RU-486: a novel approach to human fertility control. Contraception. 1987;36 (suppl):1-5. PUBMED
13. Lähteenmäki P, Heikinheimo O, Croxatto H, et al. Pharmacokinetics and metabolism of RU-486. J Steroid Biochem Mol Biol. 1987;27:859-863.
14. Heikinheimo O, Lähteenmäki PLA, Koivunen E, et al. Metabolism and serum binding of RU-486 after various single doses. Hum Reprod. 1987;2:379-385. FREE FULL TEXT
15. Deraedt R, Bonnat C, Busigny M, et al. Pharmacokinetics of RU-486. In: Baulieu EE, Segal S, eds. The Antiprogestin Steroid RU-486 and Human Fertility Control. New York, NY: Plenum Press; 1985:103-122.
16. Herrmann W, Wyss R, Riondel A, et al. Effet d'un stéroïde antiprogestérone chez la femme: interruption du cycle mentruel et de la grossess au début. C R Acad Sci III. 1982;294:933-938. PUBMED
17. Soller PC. Third world birth control: is it abortion? Drug combination gains support as alternative to surgical abortion. Med Law. 1991;10:241-247. PUBMED
18. Cousinet B, Strat NL, Ulmann A, Baulieu EE, Schaison G. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). N Engl J Med. 1986;315:1565-1570. ABSTRACT
19. Mishell DR, Shoupe D, Brenner PF, et al. Termination of early gestation with the antiprogestin steroid RU 486: medium versus low dose. Contraception. 1987;35:307-321. PUBMED
20. Birgerson L, Odlind V. The antiprogestational agent RU486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception. 1988;38:391-400. PUBMED
21. Birgerson L, Odlind V. Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and Epostane. Fertil Steril. 1987;48:565-570. PUBMED
22. Dubois C, Ulmann A, Aubeny E, et al. Contragestation par le RU486: interet de l'association a un derive prostaglandine. C R Acad Sci Paris. 1988;306:57-61. PUBMED
23. Silvestre L, Dubois C, Renault M, Rezvani Y, Baulieu EE, Ulmann A. Voluntary interruption of pregnancy with mifepristone (RU486) and a prostaglandin analogue: a large-scale French experience. N Engl J Med. 1990;322:645-648. ABSTRACT
24. Rodger MW, Baird DT. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet. 1987;2:1415-1418. PUBMED
25. Maurice J. Improvements seen for RU-486 abortions. Science. 1991;254:198-254. FREE FULL TEXT
26. United Kingdom Multicentre Trial. The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy. Br J Obstet Gynecol. 1990;97:480-486. PUBMED
27. Grimes DA, Bernstein L, Lacarra M, Shoupe D, Mishell DR. Predictors of failed attempted abortion with the antiprogestin mifepristone (RU 486). Am J Obstet Gynecol. 1990;162:910-917. PUBMED
28. Baulieu EE. Contragestation and other clinical applications of RU-486: an antiprogestin at the receptor. Science. 1989;245:1351-1357. FREE FULL TEXT
29. Jost A. Nouvelles donnes sur le besoin hormonal de la lapine gestante: grossesses partielles et anomalies foetales apres traitement par un antagoniste hormonal a dose sub-abortive. C R Acad Sci Paris. 1986;303:281-284. PUBMED
30. Wolf JP, Chillik CF, Dubois C, Ulmann A, Baulieu EE, Hodgen GD. Tolerance of prenidatory primate embryos to RU486 exposure in vitro and in vivo. Contraception. 1990;41:85-92. PUBMED
31. Lefebvre Y, Proulx L, Elie R, Poulin O, Lanza E. The effects of RU-486 on cervical ripening: clinical studies. Am J Obstet Gynecol. 1990;162:61-65. PUBMED
32. Fernandez H, Pons JC, Taylor S, Ulmann A, Frydman R. Intaaerêt du RU 486 dans les échecs d'IVG. J Gynecol Obstet Biol Reprod Paris. 1987;16:247-249. PUBMED
33. Urquart DR, Templeton AA. Mifepristone (RU 486) for cervical priming prior to surgically induced abortion in the late first trimester. Contraception. 1990;42:1991-1999.
34. Johnson N, Bryce FC. Could antiprogesterones be used as alternative cervical ripening agents? Am J Obstet Gynecol. 1990;162:688-690. PUBMED
35. Cohn M, Stewart P. Pretreatment of the primgravid uterine cervix with mifepristone 30 h prior to termination of pregnancy: a double blind study. Br J Obstet Gynecol. 1991;98:778-782. PUBMED
36. Rodger MW, Baird DT. Pretreatment with mifepristone (RU 486) reduces interval between protaglandin administration and expulsion in second trimester abortion. Br J Obstet Gynecol. 1990;97:41-45. PUBMED
37. Hill NCW, Selinger M, Ferguson J, Lopez-Bernal A, Mackenzie IZ. The physiological and clinical effects of progesterone inhibition with mifepristone (RU 486) in the second trimester. Br J Obstet Gynecol. 1990;97:487-492. PUBMED
38. Gottlieb C, Bygdeman M. The use of antiprogestin (RU 486) for termination of second trimester pregnancy. Acta Obstet Gynecol Scand. 1991;70:199-203. PUBMED
39. Cabrol D, Dubois C, Cronje H, et al. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. Am J Obstet Gynecol. 1990;163:540-542. PUBMED
40. Baulieu EE. RU486 and the early nineties. Endocrinology. 1990;127:2043-2045. FREE FULL TEXT
41. Van Santen MR, Haspels AA. Interception, II: postcoital low-dose estrogen and norgestrel in 633 women. Contraception. 1985;31:275-293. PUBMED
42. Haspels AA. Interception: postcoital estrogens in 3016 women. Contraception. 1976;14:375-381. PUBMED
43. Haspels AA. Interception, III: postcoital luteal contragestation by antiprogestin (mifepristone, RU 486) in 62 women. Contraception. 1987;35:423-438. PUBMED
44. Lähteenmäki P, Rapeli T, Kääruäinen M, Alfthan H, Ylikorkala O. Late postcoital treatment against pregnancy with antiprogesterone RU 486. Fertil Steril. 1988;50:36-38. PUBMED
45. Dubois C, Ulmann A, Baulieu EE. Contragestation with late luteal administration of RU 486 (mifepristone). Fertil Steril. 1988;50:593-596. PUBMED
46. Nieman LK, Choate TM, Chrousos GP, et al. The progesterone antagonist RU 486: a potential new contraceptive agent. N Engl J Med. 1987;316:187-191. ABSTRACT
47. McGaughran AL. The progesterone antagonist RU 486: a potential new contraceptive agent. N Engl J Med. 1987;317:575. PUBMED
48. Garzo G, Liu J, Ulmann A, Yen SSC. Effects of an antiprogesterone (RU486) on the hypothalamic-gonadotropin-ovarian-endometrial axis during the luteal phase of the menstrual cycle. J Clin Endocrinol Metab. 1988;66:508-517. FREE FULL TEXT
49. Danforth DR, Dubois C, Ulmann A, Baulieu EE, Hodgen GD. Contraceptive potential of RU486 by ovulation inhibition, Ill: preliminary observations on once weekly oral administration. Contraception. 1989;40:195-200. PUBMED
50. Woolley RJ. Contraception: a look forward: mifepristone and gossypol. J Am Board Fam Pract. 1991;4(pt 2):103-113. PUBMED
51. Panksy M, Golan A, Bukovsky I, Caspi E. Non-surgical management of tubal pregnancy. Am J Obstet Gynecol. 1991;164:888-895. PUBMED
52. Levin JH, Lacarra M, d'Ablaing G, Grimes DA, Vermesh M. Mifepristone (RU 486) failure in an ovarian heterotopic pregnancy. Am J Obstet Gynecol. 1990;163:543-544. PUBMED
53. Kenigsberg D, Porte J, Hull M, Spitz IM. Medical treatment of residual ectopic pregnancy: RU 486 and methotrexate. Fertil Steril. 1987;47:702-703. PUBMED
54. Kepes JJ. Meningiomas: Biology, Pathology, and Differential Diagnosis. New York, NY: Masson Publishing USA Inc; 1982:17-19.
55. Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry. 1958;21:89-91. FREE FULL TEXT
56. Poisson M, Pertuiset BF, Hauw JJ, et al. Steroid hormone receptors in human meningiomas, gliomas and brain metastases. J Neurooncol. 1983;1:179-189. PUBMED
57. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74:861-868. PUBMED
58. Waseda N, Kato Y, Imura H, Katura M. Effect of tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res. 1981;41:1984-1988. FREE FULL TEXT
59. Robinson SP, Jordan VC. Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res. 1987;47:5386-5390. FREE FULL TEXT
60. Bakker GH, Setyono-Han B, Portengen H, deJong FH, Foekens JA, Klijn JGM. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol. 1990;37:789-794. PUBMED
61. Klijn JGM, deJong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ, Alexieva-Figusch J. Antiprogestins: a new form of endocrine therapy for breast cancer. Cancer Res. 1989;49:2851-2856. FREE FULL TEXT
62. Mobbs BG, Johnson IE. Suppression of the growth of the androgen-insensitive R3327HI rat prostatic carcinoma by combined estrogen and antiprogestin treatment. J Steroid Biochem Mol Biol. 1991;39:713-722. PUBMED
63. Mobbs BG, Johnson IE. Changes in tumor characteristics during progression of the R3327HI experimental prostatic carcinoma. Prostate. 1990;16:127-136. PUBMED
64. Chasserot-Golaz S, Beck G, Venetianer A. Inhibition of growth by the antihormone RU-486 in different hepatoma cell lines. Mol Cell Endocrinol. 1991;82:151-158. PUBMED
65. Pater MM, Pater A. RU-486 inhibits hormonedependent oncogenesis by human papillomavirus type 16 DNA. Virology. 1991;183:799-802. PUBMED
66. Nieman LK, Chrouses GP, Nisula BC, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU-486. J Clin Endocrinol Metab. 1985;61:536-540. FREE FULL TEXT
67. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton ZP. Pituitary-adrenal response to the antiglucocorticoid action of RU-486 in Cushing's syndrome. J Clin Endocrinol Metab. 1986;63:639-642. FREE FULL TEXT
68. van der Lely AJ, Foeken K, van der Mast RC, Lamberts SWJ. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisolreceptor antagonist mifepristone (RU-486). Ann Intern Med. 1991;114:143-144. FREE FULL TEXT
69. Laue L, Gallucci W, Loriaux DL, Udelsman R, Chrousos GP. The antiglucocorticoid and antiprogestin steroid RU 486: its glucocorticoid agonist effect is inadequate to prevent adrenal insufficiency in primates. J Clin Endocrinol Metab. 1988;67:602-606. FREE FULL TEXT
70. Halbreich U, Endicott J, Goldstein S, Nee J. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand. 1986;74:576-586. PUBMED
71. Watts JF, Butt WR, Edwards RL. A clinical trial using danazol for treatment of premenstrual syndrome. Br J Obstet Gynecol. 1987;94:30-34. PUBMED
72. Halbreich U. Treatment of premenstrual syndromes with progesterone antagonists (eg, RU-486): political and methodological issues. Psychiatry. 1990;53:407-409. PUBMED
73. Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SSC. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril. 1991;56:402-407. PUBMED
74. Regelson W. RU 486: how abortion politics have impacted on a potentially useful drug of broad medical application. Perspect Biol Med. 1992;35:330-337. PUBMED
75. Regelson W, Loria R, Kalimi M. Beyond 'abortion': RU-486 and the needs of the crisis constituency. JAMA. 1990;264:1026-1027. FREE FULL TEXT
76. Philbert D, Hardy M, Gaillard-Moguilewsky, Nique F, Tournemine C, Nédélec L. New analogues of mifepristone with more dissociated antiprogesterone activity. J Steroid Biochem Mol Biol. 1989;43:413-417.